SERA PROGNOSTICS, INC. (SERA) Form 8-K — Nov 4, 2026
Sera Prognostics reported Q3 2026 results marked by strong commercial momentum: PreTRM test volumes rose 54% sequentially and roughly five-fold from Q1, ordering providers grew 34% sequentially, and Florida became the second state (after Illinois) to cover the PreTRM test under Medicaid, bringing total covered Medicaid lives to approximately 7 million. Revenue remains immaterial at $42,000 for the quarter (up 163% year-over-year), pressured by a mix shift toward low- or non-reimbursed tests. Net loss was $8.1 million, with operating expenses down 11% sequentially after June 2026 cost reductions, partially offset by commercial launch spending in Illinois and Florida.
Key figures
- Revenue
- 42000
- Total Debt
- 0
- Revenue Yoy
- 163%
- Total Assets
- 79980000
- Cash Position
- 72800000
- Quarterly cash burn
- $7.3 million
- Covered medicaid lives
- ~7 million patients
- Nine month revenue 2026
- $86,000
- Nine month net loss 2026
- $25,591,000
- Florida medicaid beneficiaries
- ~4 million
- Florida medicaid births annual
- ~90,000
- Restructuring severance expense
- $0.4 million
- Pretrm test volume growth vs 1q26
- ~5x
- Illinois medicaid fee schedule rate
- $525
- Operating expense change sequential
- -11%
- Ordering providers growth sequential
- 34%
- Pretrm test volume growth sequential
- 54%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.